No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OMCL240517C30000
- 0.48
- -1.22-71.76%
15min DelayClose May 17 15:59 ET
1.77High0.48Low
0.69Open1.70Pre Close89 Volume300 Open Interest30.00Strike Price7.07KTurnover1438.89%IV6.93%PremiumMay 17, 2024Expiry Date0.44Intrinsic Value100Multiplier0DDays to Expiry0.04Time Value100Contract SizeAmericanOptions Type0.5683Delta0.0669Gamma11.94Leverage Ratio-18.0497Theta0.0000Rho6.78Eff Leverage0.0016Vega
Intraday
- 5D
- 1D
News
Buy Rating on Omnicell Affirmed: Innovation and Growth Outlook Fuel Optimism for FY24 and Beyond
Piper Sandler Keeps Their Buy Rating on Omnicell (OMCL)
Omnicell | 10-Q: Quarterly report
Omnicell Supports Global Charity Mercy Ships With Pharmacy Technology Donation
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced continued support for the global charity Mercy Ships with the donation of solutions
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Springworks Therapeutics (SWTX) and Omnicell (OMCL)
Omnicell to Present at the BofA Securities 2024 Health Care Conference
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will present at the BofA Securities 2024 Health Care Conference in Las Vegs, NV, on Wednesday, May 15, 2024 at 3:40 p.m.
Comments
Omnicell stock is undervalued, presenting a buying opportunity. The company's future outlook is optimistic with robust cash flows expected to increase share value. However, consider other factors like financial health before investing.
Is Now The Time To Look At Buying Omnicell, Inc. (NASDAQ:OMCL)?The company's debt situation and EBIT loss of US$31m over the last twelve months raise concerns about its financial health. The balance sheet is considered far from match-fit and the stock is deemed very risky.
Omnicell's low P/S ratio suggests limited growth. Lackluster future revenue forecasts damages its value. Investors await improved performance as current weak outlook pressures stock price.
Given the falling EPS and poor performance over the last three years, future earnings performance is being considered critical for shareholders. Potential investors are cautioned to ensure they are investing in a high-quality business amid challenges.
The sharp cut to revenue forecasts suggests that investors should temper their expectations for Omnicell, Inc. Also, analysts anticipate slower revenue growth than the wider market, which could lead to increased caution among investors.
Read more